MEF2C-AS1

Across TCGA pan-cancer cohorts, MEF2C-AS1 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of MEF2C-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where MEF2C-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types MEF2C-AS1 is over-expressed in tumor, although a few such as BLCA and COAD show the opposite, repressed pattern.

BLCA, COAD, and KICH are the cancer types where MEF2C-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MEF2C-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	IV	−1.345	<.001	11	view →
COAD	Male	II,III,IV	−0.522	<.001	11	view →
KICH	Female	All	−0.378	<.001	11	view →
THCA	Male	All	−0.792	<.001	10	view →
LUSC	All	III,IV	−0.730	<.001	9	view →
UCEC	All	All	−1.447	<.001	8	view →
STAD	All	All	−0.505	<.001	7	view →
KIRP	Male	All	−0.132	<.001	7	view →
BRCA	All	III,IV	−0.612	<.001	6	view →
HNSC	Male	All	−0.204	<.001	6	view →
READ	All	All	−0.679	.001	5	view →
LUAD	Female	II,III,IV	−0.316	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

MEF2C-AS1–BLCA

Open the BLCA breakdown →